Cereno Scientific reported its Q325 results, a quarter focused on Phase II preparations for lead assets CS1 and CS014, following encouraging Phase I data for CS014, fast track designation for CS1 and the appointment of a CRO for the Phase IIb trial. Momentum strengthened post-period, with the FDA s
